anti-HCV

By Targets:	HCV (20) HCV Protease (2) Antibiotic (2) Apoptosis (1) Atg8/LC3 (1) Autophagy (1) Bacterial (2) DNA/RNA Synthesis (2) Fungal (1) Nucleoside Antimetabolite/Analog (2) Parasite (1) SARS-CoV (1)
By Research Areas:	Cancer (3) Infection (20) Inflammation/Immunology (3) Metabolic Disease (1)
Click Chemistry:	Azide (2)

Targets Recommended: HCV HCV Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N7765

Oenothein B	HCV Bacterial Apoptosis Fungal	Infection Inflammation/Immunology Cancer
Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase .

HY-N0588

Deapioplatycodin D

HCV Infection

Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .
HY-N3519

Platycodin D3

HCV Infection

Platycodin D3 is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .
HY-115988

IMB-26

HCV Infection

IMB-26 is a HCV inhibitor with an EC₅₀ of 2.1 μM. IMB-26 shows potent an anti-HCV activity .

Deapioplatycodin D	HCV	Infection
Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

Platycodin D3	HCV	Infection
Platycodin D3 is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

IMB-26	HCV	Infection
IMB-26 is a HCV inhibitor with an EC₅₀ of 2.1 μM. IMB-26 shows potent an anti-HCV activity .

HY-N3918

γ-Fagarine	HCV	Infection
γ-Fagarine is a furoquinoline alkaloid naturally occurring in Rutae Herba. γ-Fagarine has strong anti-HCV activities with IC₅₀ of 20.4 μg/mL and is also a sister chromatid exchanges (SCEs) inducer .

HY-157291

Antiviral agent 44

Antibiotic HCV Infection

Antiviral agent 44 (compound 7b) is an antiviral agent that has anti-HCV activity in vitro .

Antiviral agent 44	Antibiotic HCV	Infection
Antiviral agent 44 (compound 7b) is an antiviral agent that has *anti-HCV* activity in vitro .

HY-16750

Radalbuvir GS-9669	HCV	Infection
Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC₅₀ = 2.9 nM, GT1b EC₅₀ = 6 nM) .

HY-141882

DC-LC3in-D5	Atg8/LC3 Autophagy	Infection Inflammation/Immunology Cancer
DC-LC3in-D5 acts as an autophagy inhibitor by attenuating LC3B lipidation. DC-LC3in-D5 binds with LC3B. DC-LC3in-D5 disrupts the LC3B-LBP2 interaction with an IC₅₀ of 200 nM. DC-LC3in-D5 may contribute to anti-HCV or combination researchs in cancer through inhibiting autophagy .

HY-125182

SMCypI C31	HCV	Infection
SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC₅₀ of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC₅₀s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .

HY-112712

Cyclophilin inhibitor 1	HCV	Infection
Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin A inhibitor, with a K_d of 5 nM, shows effective anti-HCV activity, with an EC₅₀ of 98 nM for HCV 2a .

HY-146648

Cyclophilin inhibitor 3

HCV Infection

Cyclophilin inhibitor 3 (compound 7c) is a potent cyclophilin A (CypA) inhibitor with an potent anti-HCV activity (EC₅₀ of 4.2 μM) .
HY-129057

2',5-Difluoro-2'-deoxycytidine

HCV Infection

2',5-Difluoro-2'-deoxycytidine, compound 13, has potent anti-HCV activity and toxicity to ribosomal RNA (rRNA) .

Cyclophilin inhibitor 3	HCV	Infection
Cyclophilin inhibitor 3 (compound 7c) is a potent cyclophilin A (CypA) inhibitor with an potent anti-HCV activity (EC₅₀ of 4.2 μM) .

2',5-Difluoro-2'-deoxycytidine	HCV	Infection
2',5-Difluoro-2'-deoxycytidine, compound 13, has potent anti-HCV activity and toxicity to ribosomal RNA (rRNA) .

HY-N8520

Variculanol	Bacterial	Infection Cancer
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .

HY-108764

Mipomersen sodium ISIS 301012	HCV	Metabolic Disease
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has *anti-HCV* effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-148647

Mipomersen ISIS 301012 free base	HCV	Infection
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has *anti-HCV* effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-W555382

Pseudane IX 2-Nonylquinolin-4(1H)-one	HCV	Infection
Pseudane IX, a compound isolated from the leaves of Ruta angustifolia, has strong anti-HCV activity with an IC₅₀ value of 1.4 μg/mL. Pseudane IX reduces HCV RNA replication and viral protein synthesis levels .

HY-108060

Valopicitabine NM283	HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-108060A

Valopicitabine dihydrochloride NM283 dihydrochloride	HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-115989

HCV-IN-38	HCV	Infection
HCV-IN-38 is a potent, selective and orally active HCV inhibitor (EC₅₀=15 nM, SI=431). HCV-IN-38 has high anti-HCV activity and low cytotoxicity. HCV-IN-38 has a good safety and oral pharmacokinetic profile .

HY-17470

Mizoribine 4 Publications Verification NSC 289637; HE 69	HCV SARS-CoV Antibiotic Parasite	Inflammation/Immunology
Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC₅₀s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively .

HY-10443

Balapiravir 3 Publications Verification Ro 4588161; R1626	HCV DNA/RNA Synthesis	Infection
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-10443A

Balapiravir hydrochloride Ro 4588161 hydrochloride; R1626 hydrochloride	HCV DNA/RNA Synthesis	Infection
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	278 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 278 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

278 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 278 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7765

Oenothein B	Infection Structural Classification other families Classification of Application Fields Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	HCV Bacterial Apoptosis Fungal
Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase .

HY-N0588

Deapioplatycodin D	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields	HCV
Deapioplatycodin D is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .

HY-N3519

Platycodin D3	Infection Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields	HCV
Platycodin D3 is a triterpenoid saponin isolated from Platycodon grandiflorum, with anti-HCV activity .